Myotonic dystrophy type 1
MONDO:0008056Steinert disease, also known as myotonic dystrophy type 1, is a muscle disease characterized by myotonia and by multiorgan damage that combines various degrees of muscle weakness, arrhythmia and/or cardiac conduction disorders, cataract, endocrine damage, sleep disorders and baldness.
Also known as: DM1, DMPK myotonic dystrophy, MD1, Myotonic Dystrophy, Steinert disease, Steinert myotonic dystrophy syndrome, Steinert syndrome, dystrophia myotonica
56 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug AOC 1001 tested for rare muscle disease
Disease control CompletedThis study tested a new drug called AOC 1001 in 39 adults with myotonic dystrophy type 1, a genetic muscle disorder. Participants received either the drug or a placebo by IV infusion. The goal was to check safety and how the drug moves through the body. Results will help decide i…
Phase: PHASE1, PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug PGN-EDODM1 tested for muscle disease
Disease control CompletedThis early-stage trial tested a single dose of the drug PGN-EDODM1 in 24 adults with myotonic dystrophy type 1, a genetic muscle disorder. The main goal was to check safety and how the body handles the drug. The study is complete, but results are not yet available.
Phase: PHASE1 • Sponsor: PepGen Inc • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental drug AOC 1001 tested for Long-Term safety in rare muscle disease
Disease control CompletedThis study is a follow-up to an earlier trial, testing the long-term safety and effects of a drug called AOC 1001 in adults with myotonic dystrophy type 1 (DM1), a genetic muscle disease. 37 participants who completed the first study received multiple doses of AOC 1001 by IV infu…
Phase: PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Experimental drug tideglusib tested for rare muscle disease
Disease control CompletedThis phase 2 study tested the safety and effectiveness of tideglusib, an experimental drug, in 16 adolescents and adults with congenital or juvenile-onset myotonic dystrophy type 1. Participants received either 400 mg or 1000 mg of tideglusib daily. The study measured side effect…
Phase: PHASE2 • Sponsor: AMO Pharma Limited • Aim: Disease control
Last updated Jun 26, 2026 16:48 UTC
-
New blood test could replace risky prenatal procedures for genetic diseases
Diagnosis CompletedThis study aimed to develop a non-invasive prenatal test using fetal cells from a mother's blood to detect triplet repeat diseases like Huntington's disease, Fragile X syndrome, and certain types of muscular dystrophy and ataxia. Researchers enrolled 60 pregnant women at risk and…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 07:53 UTC
-
Could virtual reality help kids with a rare muscle disease read emotions better?
Symptom relief CompletedThis study tests whether virtual reality training can help children aged 6 to 16 with the childhood form of myotonic dystrophy type 1 (DM1) improve their ability to understand others' thoughts and emotions. Participants engage in social scenarios in a virtual environment, guided …
Phase: NA • Sponsor: Institut de Myologie, France • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Heart risk study for muscular dystrophy patients completed
Knowledge-focused CompletedThis study looked at 537 people with myotonic dystrophy type 1 to understand their risk of serious heart rhythm problems, including sudden cardiac arrest. Researchers tracked participants for two years to see how often these events happened and what factors might predict them. Th…
Phase: NA • Sponsor: Catholic University of the Sacred Heart • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
New study aims to sharpen tools for measuring muscle decline in common adult muscular dystrophy
Knowledge-focused CompletedThis study followed 30 adults with myotonic dystrophy type 1 (Steinert disease) and 30 healthy volunteers over three years to see how muscle strength and function change naturally over time. Researchers measured things like muscle power, walking ability, and nerve responses to fi…
Sponsor: Institut de Myologie, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
New study aims to uncover why some myotonic dystrophy patients develop low breathing
Knowledge-focused CompletedThis study followed 113 adults with myotonic dystrophy (Steinert's disease) for 5 years to find out what factors lead to low breathing (hypoventilation). Researchers measured lung function, sleepiness, fatigue, and thinking skills. The goal is to better understand which patients …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Hidden danger: muscle disease linked to deadly clots
Knowledge-focused CompletedThis study investigates why people with myotonic dystrophy type 1 are 10 times more likely to develop dangerous blood clots in the legs or lungs. Researchers will compare blood samples from 130 participants—including patients with the disease, those with a history of clots, and h…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:53 UTC